The South Korean office of the Danish pharmaceutical company Novo Nordisk recently requested the local authorities to permit ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Doctors have explained the potential pros and cons of these so-called 'skinny jabs', with everything from nausea to abdominal ...

Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

About one out of every eight adults in the U.S. has taken a GLP-1 medication, such as Trulicity, Ozempic, Rybelsus or Mounjaro — and half of these people are still ...

The acronym GLP-1 has become an increasingly popular term in the health arena, especially in the context of weight loss.

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.